Managing Insider Trading Risk in Life Sciences

This guide discusses the recent developments in insider trading cases involving executives at life sciences companies, highlighting two significant cases that have broadened the scope of liability. The first case, U.S. Securities and Exchange Commission v. Panuwat, introduced the SEC's shadow trading theory, where an executive used confidential information from his company to trade in a different company's stock. The second case, U.S. v. Peizer, marked the first criminal prosecution for insider trading based on a Rule 10b5-1 trading plan, where the executive traded while possessing material nonpublic information. The guide outlines five steps that public companies, particularly in the life sciences sector, should consider to mitigate insider trading risks. These steps include revising insider trading policies, implementing controls for trading plans, providing training on insider trading risks, reinforcing policies through organizational messaging, and investigating suspected violations. The document emphasizes the importance of understanding the evolving insider trading landscape to reduce enforcement risks.